Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
August Layoffs: A Recap of Recent Workforce Reductions in Biotech and Pharma
In recent weeks, several biotech and pharmaceutical companies have announced significant layoffs, reshaping their organizations for various reasons. Some of ...
A Breakthrough Drug for Metastatic Renal Cancer and Dialysis Patients
Oncorena has achieved a significant milestone by administering the first treatment to a patient in their Phase I/II trial of ...
How a New Drug Could Restore Brain Function After Stroke
Addex Therapeutics has made a significant stride in the field of drug discovery and development. Their recent findings, featured in ...
BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial
BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...
Alvotech Seeks Interchangeability Status for Humira Biosimilar Again
Alvotech is forging an audacious path towards a potential game-changer. CEO Robert Wessman recently unveiled a resubmission of their Biologics ...
Bavarian Nordic Abandons COVID Booster After Failing to Protect Against New Variants
Bavarian Nordic, a Danish biotech firm, has faced a crossroads that shines a light on the ever-evolving nature of the ...
Hugel Resubmits BLA for Its Botulinum Toxin Letybo to the US FDA
Hugel has just rekindled its pursuit of a groundbreaking achievement: the approval of Letybo (letibotulinumtoxinA), a potent botulinum toxin, for ...
Mallinckrodt Launches New FDA-Approved ADHD Drug Lisdexamfetamine
Mallinckrodt, a global specialty pharmaceutical company, has made waves with an announcement that’s set to reshape the Attention-Deficit/Hyperactivity Disorder (ADHD) ...
GSK’s Nucala Gets Closer to Approval for Severe Asthma in Japan
GSK has unveiled a ray of hope for millions of Japanese individuals grappling with the debilitating burden of chronic rhinosinusitis ...
Pfizer and BioNTech Get Green Light for Omicron Vaccine in Europe by CHMP
Pfizer and BioNTech have unveiled their latest breakthrough in the post COVID era. Brace yourselves for the Omicron XBB.1.5-adapted monovalent ...
NexImmune slashes staff again as cash crunch looms over its nanoparticle platform
NexImmune, the immunotherapy biotech, is once again in the spotlight for layoff as it nears the end of its financial ...
Sana cuts jobs in research area, keeps mum on numbers and programs
Sana Biotechnology, a company with a focus on CAR-T therapies, has discreetly carried out another round of layoffs, declining to ...
Bayer launches new trials for Kerendia, a potential blockbuster for heart failure
Two summers ago, Bayer introduced Kerendia (finerenone) as a treatment for chronic kidney disease (CKD) linked to type 2 diabetes. ...
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...
Elastin Biosciences Finds a Way to Restore Elastin and Treat Diseases
Longaevus Technologies is making waves with its recent spin-off from Elastin Biosciences, driven by groundbreaking preclinical results across three key ...
FDA grants breakthrough status to T-DXd for two HER2-positive cancers
Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...
Otsuka acquires Mindset Pharma, a leader in psychedelic medicines for mental health
Japanese pharmaceutical giant Otsuka is embarking on a groundbreaking acquisition, setting its sights on Canada’s Mindset Pharma, a specialist in ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
GSK boosts vaccine production with €250M facility for shingles, RSV and malaria shots
As GlaxoSmithKline (GSK) continues to expand its vaccine portfolio with the introduction of the new respiratory syncytial virus (RSV) vaccine, ...
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
Republican Governors Urge Congress to Act on U.S. Drug Shortages
Amid growing concerns over drug shortages in the US, a coalition of 11 Republican governors has penned a joint letter ...
Teva Wins License to Launch Generic Vivitrol in 2027 After Patent Settlement with Alkermes
Teva Pharmaceuticals has secured a pivotal victory in a patent dispute settlement with Alkermes, the manufacturer of Vivitrol. This settlement ...
Zevra acquires Acer for $91M to enter rare disease market with Olpruva
In a swift move that accelerates its transformation into a prominent player in the rare disease market, Zevra Therapeutics has ...
J&J cuts TB drug price by 55% after giving up patent rights
Just seven weeks after announcing its willingness to permit generic competition for the drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in ...
Sanofi’s specialty care chief Sibold leaves amid executive reshuffle
After an impressive six-year tenure steering Sanofi’s specialty care division, Bill Sibold is bidding adieu to embrace a new external ...
Emergent Launches OTC Narcan to Fight Opioid Overdose Crisis
Emergent BioSolutions has initiated the rollout of an over-the-counter (OTC) iteration of its opioid overdose treatment, Narcan, amplifying its focus ...
Mesoblast CEO Slashes Salary by 30% to Fund Cell Therapy Trial
In a bold move reflecting commitment to the company’s mission, Mesoblast’s CEO has chosen to lead by example by implementing ...
Sage slashes 40% of staff, reshuffles leadership after zuranolone setback
Sage Therapeutics is set to undergo a significant transformation by reducing its workforce by 40% following a setback in gaining ...
Takeda’s Vyvanse faces generic competition after 16 years of ADHD dominance
Vyvanse, a blockbuster drug for attention-deficit/hyperactivity disorder (ADHD) and binge-eating disorder, has been the top choice for many patients and ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
